このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

T2 Biosystems 将来の成長

Future 基準チェック /26

T2 Biosystemsは、5.8%と38%でそれぞれ年率5.8%で利益と収益が成長すると予測される一方、EPSはgrowで62%年率。

主要情報

5.8%

収益成長率

62.0%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	38.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	07 May 2024

今後の成長に関する最新情報

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

A Roadmap To T2 Biosystems Story

Mar 08

業績と収益の成長予測

NasdaqCM:TTOO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	34	-46	-41	-41	1
12/31/2025	23	-48	-42	-43	1
12/31/2024	11	-50	-41	-47	1
3/31/2024	7	-46	-47	-47	N/A
12/31/2023	7	-50	-48	-48	N/A
9/30/2023	11	-50	-49	-49	N/A
6/30/2023	13	-52	-52	-52	N/A
3/31/2023	17	-64	-50	-49	N/A
12/31/2022	22	-62	-51	-51	N/A
9/30/2022	24	-64	-51	-50	N/A
6/30/2022	28	-61	-44	-44	N/A
3/31/2022	28	-55	-45	-45	N/A
12/31/2021	28	-49	-39	-39	N/A
9/30/2021	29	-47	-38	-38	N/A
6/30/2021	27	-44	-35	-34	N/A
3/31/2021	23	-43	-38	-37	N/A
12/31/2020	18	-47	-44	-43	N/A
9/30/2020	13	-51	-45	-45	N/A
6/30/2020	10	-54	-52	-52	N/A
3/31/2020	9	-59	-48	-47	N/A
12/31/2019	8	-59	-46	-45	N/A
9/30/2019	7	-60	-45	-45	N/A
6/30/2019	8	-57	-42	-41	N/A
3/31/2019	10	-53	-42	-41	N/A
12/31/2018	11	-51	-41	-40	N/A
9/30/2018	10	-54	-42	-42	N/A
6/30/2018	9	-58	-44	-43	N/A
3/31/2018	6	-61	-48	-47	N/A
12/31/2017	5	-62	N/A	-48	N/A
9/30/2017	4	-59	N/A	-47	N/A
6/30/2017	4	-57	N/A	-47	N/A
3/31/2017	4	-56	N/A	-47	N/A
12/31/2016	4	-55	N/A	-46	N/A
9/30/2016	4	-52	N/A	-45	N/A
6/30/2016	4	-51	N/A	-45	N/A
3/31/2016	4	-48	N/A	-42	N/A
12/31/2015	3	-45	N/A	-37	N/A
9/30/2015	2	-42	N/A	-37	N/A
6/30/2015	1	-40	N/A	-33	N/A
3/31/2015	0	-38	N/A	-30	N/A
12/31/2014	0	-36	N/A	-28	N/A
9/30/2014	0	-35	N/A	-24	N/A
6/30/2014	0	-33	N/A	-22	N/A
3/31/2014	0	-31	N/A	-20	N/A
12/31/2013	0	-28	N/A	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TTOO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TTOO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TTOO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TTOOの収益 ( 38% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: TTOOの収益 ( 38% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TTOOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

T2 Biosystems 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

Consensus revenue estimates decrease by 50%, EPS upgraded

Consensus EPS estimates fall by 15%

Recent updates

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems' Survival Riddle

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems Q2 2022 Earnings Preview

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022

T2 Biosystems Receives Non-Compliance Notice from Nasdaq

T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel

Consensus forecasts updated

T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule

High number of new directors